Skip to content

Current Molecular Pharmacology

ISSN 1874-4672

2 papers in the library · 103 citations · publishing 2018-2023

Papers

Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions

Current Molecular Pharmacology October 15, 2018 Ricardo Jorge Dinis‐oliveira, Carolina Lança Pereira, Diana Dias Da Silva 101 citations

Mescaline, a hallucinogenic agent found in the Peyote cactus, has poorly understood psychoactive mechanisms despite being one of the oldest known such substances. Its effects are primarily due to interaction with serotonergic 5-HT2A-C receptors, producing euphoria, hallucinations, depersonalization, and psychoses similar to LSD and psilocybin, alongside sympathomimetic signs. The drug is mainly metabolized into trimethoxyphenylacetic acid, with several minor metabolites reported. Most intoxications are mild and unlikely to produce life-threatening symptoms; addiction and dependence are practically absent, supporting contemporary interest in therapeutic potential.

Ketamine Metabolites-waiting in the Wings as Therapeutic Candidate forDepression?

Current Molecular Pharmacology August 9, 2023 MIng Tatt Lee, Yu‐Cheng Ho 2 citations

Ketamine and its metabolite (2R,6R)-hydroxynorketamine show rapid antidepressant effects in models of major depressive disorder. The review discusses how these compounds work differently from traditional antidepressants, potentially offering faster relief for treatment-resistant depression. The FDA-approved nasal spray Spravato (esketamine) is highlighted as a clinical application. The text suggests that understanding the mechanisms of these compounds could lead to better treatments for major depressive disorder.